EyePoint Pharmaceuticals (EYPT) USPTO patents

Utility

Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use

1 Dec 22

The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis.

Jeffrey Lyle Gray, Kande K.D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier

Filed: 25 Feb 22

Utility

Compositions, Formulations and Methods for Treating Ocular Diseases

1 Sep 22

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.

Kevin PETERS, Robert SHALWITZ, John JANUSZ, Alexander SMITH

Filed: 3 Mar 22

Utility

Formulations of Tie-2 activators and methods of use thereof

16 Aug 22

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTPβ.

Kevin Peters

Filed: 23 Jun 20

Utility

Bioerodible Drug Delivery Devices

30 Jun 22

This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment.

Hong Guo, Jianbing CHEN

Filed: 17 Mar 22

Utility

Bioerodible Ocular Drug Delivery Insert and Therapeutic Method

2 Jun 22

This invention relates to implantable bioerodible inserts for delivering an active pharmaceutical ingredient to the eye.

Said SAIM, Michelle SPARKS, Dario PAGGIARINO, Basel KARZOUN

Filed: 14 Feb 22

Utility

Tie-2 activators targeting the Schlemm's canal

22 Feb 22

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta.

Kevin Peters

Filed: 28 Apr 20

Utility

Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)

23 Nov 21

The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.

Kevin Peters, Michael Allen Flynn

Filed: 17 Apr 20